Chemical structure of molecule ASP2453 Astellas KRASG12C covalent inhibitor

oral drug, covalent inhibitor of KRASG12C

effective in KRASG12C-mutated cancer models

SBDD utilizing KRAS proto-oncogene, GTPase

British Journal of Cancer

Astellas Pharma Inc.

3.      The Astellas KRASG12C covalent inhibitor, ASP2453, is an oral molecule with activity in preclinical mouse models of KRASG12C-mutated cancer at lower doses than sotorasib (AMG 510). Several KRAS inhibitors have…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.